BLISS GVS PHARMA has announced its results for the year ended March 2022. Let us have a look at the detailed performance review of the company during FY21-22.
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | % Change | |
---|---|---|---|---|
Net Sales | Rs m | 5,772 | 7,475 | 29.5% |
Other income | Rs m | 220 | 315 | 43.5% |
Total Revenues | Rs m | 5,992 | 7,789 | 30.0% |
Gross profit | Rs m | 1,066 | 447 | -58.0% |
Depreciation | Rs m | 172 | 173 | 0.6% |
Interest | Rs m | 72 | 47 | -34.5% |
Profit before tax | Rs m | 1,041 | 542 | -48.0% |
Tax | Rs m | 302 | 310 | 2.9% |
Profit after tax | Rs m | 740 | 231 | -68.7% |
Gross profit margin | % | 18.5 | 6.0 | |
Effective tax rate | % | 29.0 | 57.3 | |
Net profit margin | % | 12.8 | 3.1 |
Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | % Change | |
---|---|---|---|---|
Networth | Rs m | 7,984 | 8,088 | 1.3 |
Current Liabilities | Rs m | 2,036 | 2,331 | 14.5 |
Long-term Debt | Rs m | 326 | 232 | -28.8 |
Total Liabilities | Rs m | 10,768 | 11,087 | 3.0 |
Current assets | Rs m | 7,652 | 7,760 | 1.4 |
Fixed Assets | Rs m | 3,116 | 3,327 | 6.8 |
Total Assets | Rs m | 10,768 | 11,087 | 3.0 |
Particulars | No. of months | 12 | 12 | % Change |
---|---|---|---|---|
Year Ending | Mar-21 | Mar-22 | ||
Cash Flow from Operating Activities | Rs m | 640 | 1,355 | 111.8% |
Cash Flow from Investing Activities | Rs m | -470 | -930 | - |
Cash Flow from Financing Activities | Rs m | -208 | -237 | - |
Net Cash Flow | Rs m | -22 | 89 | - |
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | |
---|---|---|---|
Sales per share (Unadj.) | Rs | 56.0 | 72.1 |
TTM Earnings per share | Rs | 7.2 | 2.2 |
Diluted earnings per share | Rs | 7.1 | 2.2 |
Price to Cash Flow | x | 11.2 | 25.5 |
TTM P/E ratio | x | 13.8 | 35.1 |
Price / Book Value ratio | x | 2.0 | 1.3 |
Market Cap | Rs m | 15,988 | 10,324 |
Dividends per share (Unadj.) | Rs | 0.5 | 0.5 |
Current Ratio: The company's current ratio deteriorated and stood at 3.3x during FY22, from 3.8x during FY21. The current ratio measures the company's ability to pay short-term and long-term obligations.
Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 12.4x during FY22, from 15.4x during FY21. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.
Return on Equity (ROE): The ROE for the company declined and down at 2.9% during FY22, from 9.3% during FY22. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.
Return on Capital Employed (ROCE): The ROCE for the company declined and down at 7.1% during FY22, from 13.4% during FY21. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.
Return on Assets (ROA): The ROA of the company declined and down at 2.5% during FY22, from 7.5% during FY21. The ROA measures how efficiently the company uses its assets to generate earnings.
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | |
---|---|---|---|
Current ratio | x | 3.8 | 3.3 |
Debtors’ Days | Days | 2,933 | 1,918 |
Interest coverage | x | 15.4 | 12.4 |
Debt to equity ratio | x | 0.0 | 0.0 |
Return on assets | % | 7.5 | 2.5 |
Return on equity | % | 9.3 | 2.9 |
Return on capital employed | % | 13.4 | 7.1 |
To see how BLISS GVS PHARMA has performed over the last 5 years, please visit here.
Over the last one year, BLISS GVS PHARMA share price has moved down from Rs 114.0 to Rs 78.3, registering a loss of Rs 35.7 or around 31.3%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 21,672.0 (up 0.3%). Over the last one year it has moved down from 25,503.7 to 21,672.0, a loss of 3,832 points (down 15.0%).
Overall, the S&P BSE SENSEX is up 1.0% over the year.
(To know more, check out historical annual results for BLISS GVS PHARMA and quarterly results for BLISS GVS PHARMA)
BLISS GVS PHARMA currently trades at Rs 109.7 per share. You can check out the latest share price performance of BLISS GVS PHARMA here...
The revenues of BLISS GVS PHARMA stood at Rs 7,789 m in FY22, which was up 30.0% compared to Rs 5,992 m reported in FY21.
BLISS GVS PHARMA's revenue has fallen from Rs 8,407 m in FY18 to Rs 7,789 m in FY22.
Over the past 5 years, the revenue of BLISS GVS PHARMA has grown at a CAGR of -1.9%.
The net profit of BLISS GVS PHARMA stood at Rs 231 m in FY22, which was down -68.7% compared to Rs 740 m reported in FY21.
This compares to a net profit of Rs 953 m in FY20 and a net profit of Rs 1,267 m in FY19.
Over the past 5 years, BLISS GVS PHARMA net profit has grown at a CAGR of -28.5%.
The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.
This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.
The cash flow statement of BLISS GVS PHARMA reveals:
Here's the cash flow statement of BLISS GVS PHARMA for the past 5 years.
(Rs m) | FY18 | FY19 | FY20 | FY21 | FY22 |
---|---|---|---|---|---|
From Operations | 176 | 400 | 467 | 640 | 1,355 |
From Investments | 561 | -735 | -479 | -470 | -930 |
From Financial Activity | -760 | 168 | -63 | -208 | -237 |
Net Cashflow | 429 | -219 | 3 | -22 | 89 |
Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.
The ratio/financial analysis of BLISS GVS PHARMA reveals:
Here's the ratio/financial analysis of BLISS GVS PHARMA for the past 5 years.
FY18 | FY19 | FY20 | FY21 | FY22 | |
---|---|---|---|---|---|
Operating Profit Margin (%) | 20.0 | 17.5 | 15.9 | 18.5 | 6.0 |
Net Profit Margin (%) | 10.9 | 14.1 | 13.8 | 12.8 | 3.1 |
Debt to Equity Ratio (x) | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 |
Read: Latest Annual Report Analysis of BLISS GVS PHARMA
Equitymaster requests your view! Post a comment on "BLISS GVS PHARMA 2021-22 Annual Report Analysis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!